Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global ...

CLEVELAND — It's common knowledge that our personal devices can collect data about the things we watch and listen to, and that includes your smart TV too. We came across this blog post about ...

Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...